Evaluating the Economic Impact of Value-Based Pricing and Biosimilar Competition in the 2026 Uveitis Drug Sector

In early 2026, the entrance of several new adalimumab and infliximab biosimilars is significantly lowering the annual cost of treatment for patients with chronic uveitis. These 2026 economic shifts are allowing insurance companies to lower the "prior authorization" hurdles that previously delayed access to life-saving biological therapies. In early 2026, many health systems are adopting "value-based pricing" models where the cost of a drug is tied to its success in maintaining long-term visual acuity. This 2026 competitive environment is forcing pharmaceutical manufacturers to innovate further, focusing on drugs with longer dosing intervals and fewer side effects to justify their place in the market.